The Use of Cilostazol in Patients With Diabetic Nephropathy
Diabetes Mellitus, Type 2, Diabetes Complications
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetic nephropathy, Macroalbuminuria, Pletaal
Eligibility Criteria
Inclusion Criteria: Male or female patients aged between 20 and 70 years Patients with Type 2 diabetic mellitus A fasting urinary albumin/creatinine ratio greater than or equal to 30 mg/mmol or 24 hour urinary albumin excretion greater than or equal to 300 mg/day in two urine collections during the baseline period Two consecutive serum creatinine levels during baseline period which meet the following requirements: Women: between 80 umol/l and 250 umol/l (inclusive) Men: between 105 umol/l and 250 umol/l (inclusive) Written informed consent Exclusion Criteria: Pregnancy Known allergy to cilostazol or aspirin Congestive heart failure (NYHA class III to IV) Severe liver impairment (greater than or equal to 3 times ULN of ALT) Serum potassium levels greater than or equal to 5.5 mmol/l on 2 consecutive specimens
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Cilostazol
Placebo
Cilostazol 100 mg twice daily